Zoetis Inc. (NYSE:ZTS – Free Report) – Zacks Research upped their Q1 2025 earnings per share estimates for shares of Zoetis in a report issued on Wednesday, September 4th. Zacks Research analyst E. Bagri now anticipates that the company will earn $1.49 per share for the quarter, up from their prior forecast of $1.48. The consensus estimate for Zoetis’ current full-year earnings is $5.84 per share. Zacks Research also issued estimates for Zoetis’ Q2 2025 earnings at $1.66 EPS, FY2025 earnings at $6.41 EPS, Q1 2026 earnings at $1.66 EPS, Q2 2026 earnings at $1.79 EPS and FY2026 earnings at $6.98 EPS.
Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the prior year, the business earned $1.41 earnings per share. Zoetis’s revenue for the quarter was up 8.3% compared to the same quarter last year.
View Our Latest Stock Report on Zoetis
Zoetis Price Performance
Shares of NYSE:ZTS opened at $189.20 on Friday. The company’s fifty day moving average price is $181.22 and its 200-day moving average price is $174.57. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The firm has a market capitalization of $85.72 billion, a price-to-earnings ratio of 36.45, a PEG ratio of 2.87 and a beta of 0.88. Zoetis has a one year low of $144.80 and a one year high of $201.92.
Hedge Funds Weigh In On Zoetis
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Sanctuary Advisors LLC purchased a new stake in shares of Zoetis during the second quarter valued at approximately $19,525,000. Clear Rock Advisors LLC increased its position in shares of Zoetis by 8.7% in the second quarter. Clear Rock Advisors LLC now owns 16,427 shares of the company’s stock valued at $2,848,000 after acquiring an additional 1,314 shares during the period. Clearbridge Investments LLC raised its stake in shares of Zoetis by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after acquiring an additional 166,517 shares during the last quarter. KPP Advisory Services LLC boosted its holdings in shares of Zoetis by 7.4% during the second quarter. KPP Advisory Services LLC now owns 5,000 shares of the company’s stock worth $867,000 after purchasing an additional 345 shares during the period. Finally, Ted Buchan & Co bought a new stake in shares of Zoetis in the second quarter worth about $231,000. 92.80% of the stock is currently owned by institutional investors.
About Zoetis
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Stories
- Five stocks we like better than Zoetis
- How is Compound Interest Calculated?
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- Investing In Preferred Stock vs. Common Stock
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- How to Invest in the Best Canadian Stocks
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.